What is lu 177 psma?

Lu-177 PSMA is a synthetic peptide molecule that specifically targets prostate-specific membrane antigen (PSMA), which is found on the surface of prostate cancer cells. Lu-177 PSMA is radiolabeled with the beta-emitting radioisotope lutetium-177, which allows for targeted radiation therapy of prostate cancer cells while minimizing damage to healthy surrounding tissue.

Clinical studies have shown that Lu-177 PSMA therapy can effectively target and shrink prostate cancer tumors in patients with advanced, metastatic disease. It is typically administered as a series of intravenous injections, with dosage and treatment duration depending on the patient's individual disease status and response to therapy.

Lu-177 PSMA therapy is still undergoing clinical trials and is not yet widely available outside of research settings. However, it has shown promise as a potential treatment option for patients with advanced prostate cancer who are no longer responsive to other forms of therapy.